31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The Mini-Mental State Examination (MMSE) is the most widely used instrument for the screening of cognitive impairment worldwide, but its ability to produce valid estimates of dementia in populations of low socioeconomic status and minimal literacy skills has not been adequately established. 4 key findings →
Design: cross-sectional Participants: 1,933 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease (AD) is the most common form of dementia worldwide. 4 key findings →
Design: cross-sectional Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The BHA has excellent performance characteristics in detecting cognitive impairment including dementia and MCI in a Hispanic population in Cuba and outperformed the MoCA. 2 key findings →
Design: cross-sectional Participants: 146 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings indicate that AD patients present impairments in some key functional abilities, such as gait, turning and sitting, sit to stand, and reaction time, both in mild and moderate AD. 4 key findings →
Design: cross-sectional Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
Although a small-scale study (n = 60), it suggests that older adults operate in larger geographic spaces than in the areas where they reside. 5 key findings →
Design: cross-sectional Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among these patients, 29 were diagnosed with CHE by the PHES test (35.36% prevalence) and 28 of those obtained equal diagnosis by the Stroop EncephalApp (96.6% sensitivity). 5 key findings →
Design: cross-sectional Participants: 82 Evidence: low
Full summary, score breakdown and related studies → Original source
The protein beta-amyloid is said to be central to the disease process of Alzheimer's disease (AD). 4 key findings →
Design: cross-sectional Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cross-sectional observational study. 4 key findings →
Design: cross-sectional Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The independent and combined effects of physical and cognitive domains of frailty in predicting the development of mild cognitive impairment (MCI) or dementia are not firmly established. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Physical performance tests are important for assessing the effect of physical activity interventions in older people with dementia, but their psychometric properties have not been systematically established within this specific population. 4 key findings →
Design: cross-sectional Participants: 58 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The BHA had excellent combined sensitivity and specificity to detect dementia and MCI, including MCI due to diverse etiologies. 2 key findings →
Design: cross-sectional Participants: 347 Evidence: low
Full summary, score breakdown and related studies → Original source
T2D-related brain dysfunction in mid-life manifests as attentional loss accompanied by evidence of subtle neurodegeneration and global reduction in cerebral metabolism, in the absence of overt cerebrovascular disease. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
We report the development and validation of an MDS-based cognitive index, the MDS Cognition Scale (MDS-COGS), by evaluating it against two popular dementia rating scales, the Global Deterioration Scale (GDS) and the Mini-Mental State Examination (MMSE). 4 key findings →
Design: cross-sectional Participants: 133 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The purpose of this study was to assess the cross-sectional prevalence and characteristics of anxiety among patients with Alzheimer's disease (AD), as compared with patients with frontotemporal dementia (FTD), patients with vascular dementia (VaD), and normal control subjects. 4 key findings →
Design: cross-sectional Participants: 115 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 893 participants with average age 93 years (range 90-102), 43 % had SMC. 5 key findings →
Design: cross-sectional Participants: 893 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Scores on the full and abbreviated versions of the MoCA can be linked directly to the MMSE. 1 key finding →
Design: cross-sectional Participants: 199 Evidence: low
Full summary, score breakdown and related studies → Original source
The aim of the study was to investigate the value of the Mini-Mental State Examination (MMSE) for use by general practitioners (GPs) in a group of elderly patients in whom the GPs are considering a dementia diagnosis. 4 key findings →
Design: cross-sectional Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Behavioural and psychological symptoms of dementia (BPSD) are non-cognitive symptoms commonly associated to Alzheimer's disease (AD). 4 key findings →
Design: cross-sectional Participants: 1,014 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Elevated FSH and reduced LH may be associated with poorer cognition and an increased risk of AD-D in very old Chinese adults, particularly in males. 5 key findings →
Design: cross-sectional Participants: 509 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State Examination (MMSE) measures global cognitive performance and is often used as a screening test for dementia. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The impact of cognitive impairment on activities of daily living (ADL) is being used as a major criterion for differentiating between mild cognitive impairment (MCI) and dementia. 4 key findings →
Design: cross-sectional Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 101 FTD patients (64 ± 8 years, 53 men), 230 AD patients (65 ± 10 years, 84 men), and 173 CTR (59 ± 15 years, 67 men) were studied. 5 key findings →
Design: cross-sectional Participants: 101 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin). 5 key findings →
Design: cross-sectional Participants: 3,074 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ANOVA and Bayesian t-test found no significant differences between the task when it was remotely self-administered by participants at home compared to when it was taken under controlled lab conditions. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Primary healthcare providers are deficient in knowledge of dementia Alzheimer's or cognitive assessment tools, and so they do not routinely carryout cognitive screening in elderly patients during clinic visits. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events